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RESUMEN
Los tumores deben evadir la respuesta inmunológica para ser
clínicamente detectables en el paciente. A estos fines, las células
cancerosas han desarrollado múltiples estrategias para eludir el
ataque inmunológico. Estos mecanismos conspiran en estadíos
avanzados de un tumor limitando la habilidad del sistema inmu-
ne para inhibir el crecimiento tumoral y la efectividad de estra-
tegias de inmunoterapia en cáncer. Desde la biología tumoral a
la clínica, en el presente artículo expondremos los más impor-
tantes mecanismos utilizados por tumores para evadir la respuesta
inmunológica y su potencial impacto en el diseño de estrategias
de inmunoterapia. 
PALABRAS CLAVE: Escape tumoral/ Presentación antigeni-
ca/ Apoptosis/ Contraataque/ Fas ligando/ Galectina-1.
ABSTRACT
Tumors must circumvent the immune response of the host to
become clinically detectable. For this purpose, malignant cells
have devised multiple strategies to thwart immune attack. These
mechanisms are suggested to conspire in advanced stages of can-
cer to limit the ability of the immune system to restrain the tumor
and the effectiveness of immunotherapy strategies to successfully
eradicate malignant cells. From tumor biology to cancer immu-
notherapy and back again, we will summarize here some of the
most important mechanisms used by tumors to evade the immu-
ne response and their potential impact in the design of cancer
immunotherapy strategies.
KEY WORDS: Tumor-immune escape/ Antigen presentation/
Apoptosis/ Counterattack/ Fas ligand/ Galectin-1.
A BRIEF INTRODUCTION: FROM IMMUNE
SURVEILLANCE TO TUMOR-IMMUNE ESCAPE
All living organisms are exposed to different external
insults such as viruses, bacteria, fungi, parasites and toxins,
among others. To overcome these adverse stimuli, vertebrates
have successfully developed a sophisticated system of
protection against such foreign pathogens. As a consequence,
the immune system displays different and complex innate
and adaptive mechanisms in which several cell types are
involved.
The first suggestion of a pivotal role of the immune
system in recognizing tumor cells as foreign was postulated
by Paul Erlich early during the 20th century(1). Erlich
postulated the concept that the immune system would
protect the organism, namely «the self», detecting and
eliminating the «non-self». The idea that tumor cells are
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considered as «non-self» and can be recognized and eliminated
by T-cell mediated mechanisms was controversial for many
years. The genetic and biochemical changes that a normal
cell undergoes during its transition to a malignant cell
can frequently lead to the production of new antigens
that are not present in normal cells. These new antigens are
called tumor-specific antigens (TSA). 
However, the first experimental evidence supporting
the notion that tumors can induce an immune response
emerged four decades later. The original observations of
Gross(2), Foley(3), and Prehn(4) demonstrating that different
inbred strains of mice can develop resistance to tumor
transplantation by preimmunization with the same tumor,
were confirmed in different experimental models by several
researchers(5, 6). Nevertheless, those and other experimental
results, have not received wide acceptance among the
community of tumor biologists, as it was believed that MHC
and not TSA antigens would be responsible for the observed
immune response. In spite of this controversy, Burnet
and Thomas provided a re-birth of Erlich’s hypothesis(7, 8)
and developed the theory of tumor-immune surveillance.
The authors proposed that the majority of the tumors, which
appeared frequently, were eliminated efficiently by the
immune system, even before they could be clinically detectable.
This seminal theory not only induced a great deal of
experimental work that meant a significant advance in
tumor immunology, but also opened new avenues for
immunological intervention in order to eradicate primary
tumors and metastases.
THE «GREAT CONTRADICTION»: 
AN IMMUNOCOMPETENT HOST CANNOT BEAT
AN IMMUNOGENIC TUMOR 
From its very beginning, the immune surveillance theory
had strong supporters but also strong detractors. In spite
of the evidences obtained from different experimental
models, supporting the existence of an immune response
against tumors(9), several arguments were posed against
this theory(10). The lack of increase of tumor incidence in
nude mice, which are congenitally athymic and, therefore,
incapable of mounting a T cell response, was the main
experimental fact that seemed to defeat Burnet’s theory.
Nevertheless, the experimental evidence obtained later
finally confirmed Burnet’s hypothesis. It was clearly
demonstrated that natural immunity in nude mice could
control tumor development. Moreover, it was also shown
that nude mice indeed develop extrathymic T cells. After
several controversial discussions, this theory is at present
in good health, due to the emergence of new experimental
data supporting the concept of immunosurveillance(11-14).
However, if we accept that the immune system of an
immunocompetent host is able to detect and respond to the
new antigens displayed by the tumors, an important
contradiction emerges when we confront this situation with
the fact that, very frequently, the immune system is not able
to cope with the tumor that grows and, eventually, kills the
host. Several mechanisms, known as tumor escape
mechanisms, appear to be responsible for the lack of an
effective immune response against the tumors. 
Tumors must circumvent the immune response of the
host to become clinically detectable. For this purpose,
malignant cells have devised multiple strategies to evade
or thwart the immune attack. These mechanisms are suggested
to conspire in advanced stages of cancer to limit the ability
of the immune system to restrain the tumor and the
effectiveness of immunotherapy strategies to successfully
eradicate malignant cells. In the next sections we will critically
discuss some of the most important mechanisms developed
by tumors to evade immune recognition and resist immune
attack (Figure 1).
TUMOR-IMMUNE ESCAPE STRATEGIES
Alterations in the expression and function of Major
Histocompatibility Complex (MHC) molecules
The success in tumor elimination by CD8+ cytotoxic T
lymphocytes (CTLs) relies on the efficient presentation of
the tumor antigen-derived peptides by MHC class I molecules.
Effector T cells specifically recognize those peptides associated
with MHC-I and exert their cytotoxic effect by inducing
tumor cell apoptosis. Any alteration of the antigen presentation
machinery will alter the generation of an effective immune
response. 
Cancer cells have developed multiple mechanisms aimed
at eliminating or, at least, weakening the adaptive immune
response. Such a strategy is clearly evidenced by the
demonstration of a frequent down-regulation of the expression
of MHC class I antigens in several tumor types. The loss of
these molecules results in decreased ability to present
peptides derived from tumor antigens, thus making these
cells resistant to CTLs. Complete loss of class I or loss of
single alleles are frequently seen and more than half of all
tumors may have one of these alterations. It has been reported
by several laboratories that the down-regulation or loss of
MHC class I expression prevents the recognition of tumor
antigens and the lysis by CTLs. In fact, down-regulation of
HLA-A and HLA-B alleles is quite common in different
tumor types(15-17). Moreover, downregulation of MHC I
expression and function has been demonstrated to have an
important prognostic value(18, 19). A number of studies have
been carried out to assess the different HLA phenotypes
and the molecular mechanisms leading to those phenotypes,
which are regulated at least in part, through changes in
oncogenic factors(20). Complete loss of expression of the
HLA class I alleles is a phenotype found in cervical
carcinomas(21), bladder carcinomas(22) and melanomas(23, 24),
among others. In the majority of the cases the HLA loss is
caused by different mutations involving β2-microglobulin
genes. It has been proposed that tumor suppressor genes
and genes implicated in the immune response could undergo
inactivation by the same molecular mechanisms(20). Haplotype
loss is the second HLA phenotype that has been described.
This alteration is caused by the hemizygous loss of HLA-
A, -B and –C alleles, and the underlying mechanism is the
presence of large deletions in chromosome 6(25, 26). Allelic
loss of single HLA alleles defines a third HLA phenotype
that is caused by a wide array of genetic defects including
point mutations, frame shifts or deletions. These kind of
genetic alterations have been detected in melanomas and
colorectal carcinomas(27).
It has been well established that cells that express lower
levels of HLA-A and HLA-B molecules are more susceptible
to lysis by the natural cytotoxicity exerted by NK cells(28).
Such a condition revealed another mechanism of evasion
by cancer cells involving the expression of non classical
HLA molecules such as HLA-G and HLA-E, which belong
to the group MHC class Ib. This group of molecules is
involved in immunoregulation, acting as inhibitory signals
for NK cell cytotoxicity(29). It has been shown that expression
of HLA-G by melanoma cells contributes to cell evasion of
the immune response by inhibiting NK cell recognition(30).
Furthermore, recent evidence indicates that the inhibition
of the interactions between NKG2D and its ligands on tumor
cells (i.e MICA and MICB proteins) may result in tumor
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Figure 1. Mechanisms of tumor-mediated immune evasion: A) alterations (down-regulation or loss) in MHC expression and function in tumor cells; B) alterations
in tumor antigen expression and/or processing; C) alterations in the expression of costimulatory molecules; D) alterations in signal transduction molecules (p56lck;
p59fyn; CD3-ζ, and others); E) induction of T cell apoptosis by: CD95/CD95L, PD-1/PD-L1, or galectin-1; F) tumor-induced immunosuppression by
regulatory T cells, cytokines or galectin-1.
A) Down-regulation  or
loss of MHC I molecules
B) Alterations in antigen
expression or processing
C) Down-regulation or
loss of costimulatory
molecules
D) Alterations in signal
transduction molecules
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cell evasion of NK cell responses(11, 12). The identification
of different strategies used by tumors to avoid immune
surveillance and the elucidation of the molecular mechanisms
involved in these strategies are crucial for the development
of novel therapeutic approaches directed to restore an
effective immune response.
Alteration in Tumor Antigen Expression and the Antigen
Processing Machinery 
In recent years a great progress has been made in the
identification of tumor-specific antigens (TSA), derived from
antigens localized on the surface of tumor cells. Tumor
antigens can be classified into two types: 1) those that are
unique to transformed cells and do not appear in normal
cells (TSA) and 2) those called tumor-associated antigens
(TAA), which are frequently found on the surface of tumor
cells but are also expressed on the surface of normal cells
during the embryonic or fetal life (oncofetal antigens), in
selected organs after birth, or in normal cells but at much
lower concentration than on tumor cells. 
Research over the past decade has led to the identification
of different tumor antigens recognized by T cells and the
elucidation of their structure and nature at the molecular
level(31-35). The presence of specific antigens is critical for the
development of an antitumor immune response. Therefore,
if the tumor finds the way of downregulating, modifying
or losing its own antigens, it will have found an efficient
tactic for avoiding immune recognition. Actually, it has been
demonstrated that several of these modifications take place
in different tumor models. 
Independently of the alterations in the expression of
HLA class I antigens, a wide array of modifications in the
structure and/or the expression of TSA have been observed
in different tumor types. Besides the intrinsic heterogeneity
of antigen expression among different tumors, a down-
regulation of antigen expression has been demonstrated,
which could range from decreased expression levels to a
complete loss of one or more tumor antigens(27, 36-38). Thus,
antigen-loss variants that appear or remain within the tumor,
particularly after immunotherapy(39, 40) have a selective
growth advantage, leading to a more malignant tumor.
Melanoma is a prototype tumor in which down-modulation
of several differentiation antigens (including Melan-A/MART-
1 and tyrosinase)(41-43) has been clearly demonstrated. Down-
regulation of Melan-A/MART-1 antigen expression by
different mechanisms (including antigen silencing via its
promoter)(44) avoids recognition by Melan-A/MART-1-
specific T cells and contributes to tumor-immune escape. 
A second immune escape strategy based on modifications
of tumor antigens has recently been demonstrated. Tumors
can take advantage of the mechanism of antigenic drift, like
viruses, and generate point mutations that change the amino
acid sequence of the antigen(45, 46). Then, cells harboring
the new antigen variants are selected by their growth
advantage, since the specific T-cell response elicited by the
original tumor is directed toward an antigen that is no longer
represented on the tumor cell surface.
Moreover, even if the expression of HLA I molecules
and tumor antigens is conserved, the induction of a specific
cytotoxic T cell response may be impaired because of the
presence of alterations in the antigen-processing machinery(27).
Down-regulation of the transporters of peptides related to
antigen processing TAP-1 and TAP-2, has been associated
with the malignant potential of murine(47) and human(48)
tumors.
A retrospective analysis of the classical theory of «genetic
instability» described by Peter Nowell in 1976(49) provides
support to the different tumor cell variants that will harbor,
heterogeneity not only in MHC molecules expression, but
also in the expression of tumor antigens. The consequence
of such variety of phenotypes is rapidly observed: the success
of the patrolling immune cells in eradicating susceptible
cancer cells is reverted towards rapid tumor growth. These
tumor cell variants will have increased malignancy, tumor
progression and, finally, metastatic dissemination.
Alterations in the Expression of Costimulatory or
Adhesion molecules 
Naïve T lymphocytes require at least two different
extracellular signals in order to activate and differentiate
into effector cells. The binding of the MHC-peptide complex
to its specific receptor (TCR-CD3 complex) and to the co-
receptors CD4 or CD8, provides the first signal required for
the development of a specific immune response. However,
this signal is not sufficient for full activation of T cells,
requiring the participation of a second signal provided by
costimulatory molecules (B7-1/CD80 and B7-2/CD86)
expressed by antigen presenting cells (APC). However, other
molecules are also involved in nonspecific adhesion
mechanisms that are required for the interaction and
immunological synapse between effector cells and target
cells. Some of these interactions involve ICAM-1 (CD54)
binding to LFA-1, CD40L binding to CD40, and members
of the TNF receptor family(46). The majority of the tumors
are derived from parenchymal or mesenchymal cells that
do not express B7 molecules. Moreover, cells that normally
express B7 can down-regulate its expression during the
process of tumor progression(50). Thus, the ability of tumor
cells to effectively present tumor antigen derived-peptides
might be severely impaired. Consequently, that lack of
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costimulation could be an important mechanism of evasion
of the immune response, even if tumor cells express normal
levels of MHC-I and TSA(51, 52). In this regard it has been
recently demonstrated that low surface expression of B7-
1/CD80 represents an immune escape mechanism in colon
carcinoma(53). Tirapu and colleagues showed that silencing
of CD80 by interfering RNA led to loss of tumorigenicity
of CT26 colon carcinoma in immunocompetent, but not
immunodeficient Rag-/- mice(53).
The differentiation of CTLs is stimulated by activated
helper T cells and requires the presence of MHC molecules
on APC. Thus, for the induction of effective anti-tumor
immune responses, a cross-priming by APCs that express
costimulatory and MHC molecules is usually required. In
this context, a decrease or lack of an adequate cytotoxic anti-
tumor response would be provoked by APCs that are not
able to efficiently present tumor antigens and activate helper
T cells.
Induction of T cell apoptosis: «Tumor Counterattack»
Following the principle that the best defense is a timely
attack, cancer cells not only resist immune attack, but have
also devised strategies of tumor counterattack.
The CD95/CD95L System
Apoptosis mediated by Fas (CD95)/Fas L (CD95L)
interactions is critical for the regulation of the biology and
homeostasis of normal tissues. The Fas receptor belongs
to the tumor necrosis factor (TNF) family of receptors involved
in proliferation and apoptosis and is characterized by an
intracellular domain, called «the death domain». Fas ligand
(FasL) is a type II transmembrane protein which functions
by inducing apoptosis of Fas-bearing cells(54).
In 1995, D.L Vaux observed that FasL-expressing Sertoli
cells were not rejected when transplanted into allogeneic
mice(55). This observation was supported by the finding of
FasL expression in the eye(56), and allowed the conclusion
that FasL expression confers immunological privilege to
selected tissues under physiological and pathological
conditions. A few years later, the interaction of FasL on
tumor cells with its specific receptor Fas on T lymphocytes
was implicated in tumor cell evasion of immune
surveillance(57).
Binding of FasL to Fas leads to oligomerization of receptors
and recruitment of FADD and the pro-caspase 8; these
molecules together form a protein complex called the death-
inducing signaling complex (DISC). In the DISC, pro-caspase-
8 is autocatalytically cleaved and then activates further
effector caspases directly or via a mitochondrial pathway,
which cleave cellular substrates leading to the typical
biochemical and morphological changes of apoptosis. The
Fas signaling pathway is regulated by many pro- and
anti-apoptotic factors, including members of the Bcl-2 family
which regulate apoptosis at the mitochondrial level, FLIPs
(FLICE-inhibitory proteins) which interfere with the initiation
of apoptosis directly at the level of death receptors, and
IAPs/ survivin which bind to and inhibit caspases and
apoptosome formation(58).
Expression of FasL has been reported in solid tumors of
nonhematopoietic origin, including colon, hepatocellular
carcinoma, melanoma, astrocytoma, lung carcinoma, ovarian
carcinoma, esophageal carcinoma, glioblastoma, renal cell
carcinoma, and head and neck carcinoma. However,
considerable heterogeneity in surface expression of FasL
has been detected even within a particular lineage of tumor(59).
Although unspecific staining of certain FasL antibodies has
been demonstrated(60), it has been shown that FasL-positive
tumor cells can kill Fas-positive T cells in vitro, demonstrating
functional FasL expression(61).
A number of tumors are resistant to apoptosis and express
functional FasL constitutively or after chemotherapy. This
situation may enable tumor cells to delete anti-tumor
lymphocytes and to suppress anti-tumor immune responses,
a phenomenon called «tumor counterattack»(62). Several lines
of evidence support the involvement of the Fas system in
tumor counterattack. Fas/FasL interactions are proposed
to be an important mechanism for the maintenance of immune
privilege in selected organs including the eye, placenta,
testis, and the central nervous system(63). Also, various animal
models have been used to demonstrate the ability of FasL
expressed on tumors to down-regulate anti-tumor immune
responses(64, 65). However, certain experimental evidence
seems to contradict the FasL counterattack hypothesis. It
has been reported that overexpression of FasL on tumor
cells does not confer immune privilege but, instead, induces
a strong inflammatory response that accelerates tumor
rejection. These reports propose that FasL has a pro-
inflammatory function and that gene transfer of FasL can
be used in tumor eradication. It has been suggested that
locally expressed FasL acts on surrounding cells to induce
the production of IL-8 or other leukocyte chemoattractants(66).
Other authors reported that FasL induces the processing
and release of IL-1β, which in turn may be responsible for
the infiltration by neutrophils(67).
The in vivo consequences of FasL expression on tumors
are far from clear. So far, many studies of tumor counterattack
have been published, but the results are confusing and
contradictory because many factors may influence FasL
activity in vivo. The different levels and the kinetics of FasL
expression on tumor cells may be of particular relevance in
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tumor-immune system interactions. The sensitivity of T cells
to Fas-mediated apoptosis varies considerably depending
on the activation status of T cells. Also, T-cell sensitivity
to Fas-mediated apoptosis is modulated by many factors,
particularly by signaling through various receptors and
cytokines(68). The consequences of FasL expression may also
depend on the tumor microenvironment. Various site-specific
factors may have a critical impact on the physiology of
immune cells, on the interaction of immune and tumor cells
and on the tumor itself. In addition the release of different
type of cytokines, such as TGF-β and IL-10, the oxygen levels
(hypoxia or normoxia), the extent of vascularization and
the accessibility to immune cell infiltration, may also influence
Fas L-mediated immune privilege.
A further complicating aspect in tumor-immune escape
mediated by FasL is the role of soluble FasL(69). Soluble FasL
differs functionally from the membrane-bound form and
its biological function is controversial. In some studies soluble
FasL was cytotoxic(70), while in other studies Fas L shedding
resulted in the absence of killing activity(71). Finally, other
death factors, such as TNF and TRAIL, have also been shown
to kill T cells(72) and, thus, might contribute to the suppression
of anti-tumor immune responses.
Taken together, the evidence presented suggest that
tumor counterattack may be a powerful mechanism of tumor
immune escape. To further understand its relevance under
physiological and pathological conditions, it will be essential
to use defined experimental systems in which all the above
mentioned key elements could be controlled or carefully
modulated. Thus, inhibition or blocking of tumor counterattack
mechanisms might be beneficial for cancer therapy.
Tumor-induced Immunosuppression: Regulatory 
T cells and Cytokines
Recently, a subset of T cells, co-expressing CD4 and
CD25 (IL-2Rα chain), with unique immune regulatory
properties has been described(73). Regulatory CD4+CD25+
T cells (Treg) contribute to the prevention of autoimmune
disorders by controlling the activity of autoreactive T
lymphocytes and by inhibition of the proliferation of effector
T cells. It has been suggested that CD4+CD25+ regulatory
T cells may also contribute to immune tolerance at the
tumor microenvironment and that depletion of these
regulatory cells might be advantageous for boosting the
anti-tumor immune response(74). These cells constitute
approximately 5-10% of the total CD4+ T cell population
in both humans and rodents, and their removal induces
autoimmune disease in target tissues(75). Besides expressing
the CD25 receptor, Tregs express other molecules including
the cytotoxic T lymphocyte-associated protein-4 (CTLA-
4), a glucocorticoid-induced TNF receptor family-related
protein (GITR) and FoxP3 (a forkhead family transcriptional
regulator). Although none of them is a distinct marker of
the lineage, FoxP3 has turned out to be a useful marker as
well as a critical factor for the differentiation and function
of these cells(76). Association of these markers with the
immunoregulatory activity of T regs has provided insights
for the identification and molecular characterization of
this particular cell subset. It has been recently demonstrated
that Gr-1+ CD115+ immature myeloid suppressor cells
can mediate the development of tumor-induced T regulatory
cells in tumor-bearing hosts(77). 
In addition to CD4+ CD25+ FoxP3+ natural Treg, recent
studies also report the identification of inducible T regulatory
cells (Tr1)(78). The immune regulatory function of Tr1 cells
has been attributed to their capacity to secrete
immunosuppressive cytokines such as IL-10 and TGF-β(79).
In contrast Treg can suppress the effector immune response
by cell-cell contact or by release of immune suppressive
factors(80). 
However, besides of being responsible for the suppressive
effect of regulatory T cells, the unresponsiveness of the
immune system in patients with cancer has been attributed
to the secretion of immunosuppressive cytokines by the
tumor itself. IL-10 is an anti-inflammatory cytokine that
participates in the regulation of the immune response at
several levels. IL-10 inhibits cytokine production of activated
T and NK cells and of monocytes/macrophages and it blocks
the antigen presenting activity of macrophages and dendritic
cells, along with many other immunological functions. High
IL-10 production was found to be associated with the
immunosuppressive activity frequently observed in tumor-
bearing hosts, and it was speculated that overproduction
of IL-10 could be responsible of tumor cell evasion of immune
responses(81). TGF-β is another cytokine that inhibits activation,
proliferation, and activity of lymphocytes(82). High levels of
this immunosuppressive cytokine are often found in several
malignancies and have associated with poor prognosis and
lack of response to immunotherapy(83). Recent evidence
indicates that TGF-β acts on cytotoxic T lymphocytes (CTL)
to specifically inhibit the expression of different cytolytic
gene products; namely perforin, granzyme A, granzyme B,
Fas ligand, and IFN-γ, which are collectively responsible
for CTL-mediated tumor cytotoxicity(84). Consistently,
blockade of TGF-β signaling allows the generation of a potent
antitumor immune response(85).  
Natural regulatory T cells are found at a higher frequency
in peripheral blood of cancer patients and may induce
tolerance at the tumor microenvironment, facilitating
metastatic spread of cancer cells(86). When Treg were depleted
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in mice, transplantable tumors were efficiently rejected by
the host immune system(87). Interestingly, Dannull and
colleagues recently demonstrated that vaccine-mediated
antitumor immunity can be significantly enhanced following
depletion of regulatory T cells(88). In addition, administration
of anti-CD25 monoclonal antibody and/or anti-CTLA-4 for
a limited time period also provoked effective tumor-specific
immunity against syngeneic tumor cells(89). 
It has been postulated that an imbalance in Th1/Th2
cytokine production may also be responsible for the
development of cancer, with a shift toward a Th2 response
and induction of immunosuppressive cytokines including
IL-10, IL-4 and IL-6(90). Cyclophosphamide (Cy) is an alkylating
agent widely used in cancer chemotherapy. It has bimodal
effect on the immune system, depending of the dose and
schedule of administration(91). We have demonstrated that
a single low-dose of Cy induced a Th2/Th1 shift in the
cytokine profile of syngeneic lymphoma-bearing rats, which
may be responsible of its antimetastatic effect. Such a treatment
reduced the splenic production of IL-10, TGF-β and nitric
oxide, restoring the lymphoproliferative capacity(92-94).
Cyclophosphamide has been demonstrated to have selective
toxicity to suppressor T cells(95) and, more recently, to
CD4+CD25+ regulatory T cells(96), thus promoting tumor
growth. Currently, we have preliminary evidence in an
experimental lymphoma model supporting the role of Cy-
mediated immunopotentiation through a mechanism of
selective toxicity against CD4+CD25+ T cells (unpublished
results). 
T regulatory cells have been proposed as key regulators
of antitumor immune responses and their induction is
considered a mechanism of tumor-immune escape. The idea
that removal and/or inhibition of CD4+CD25+ regulatory T
cells or inducible Tr1 cells can abrogate immunological
unresponsiveness to syngeneic tumors, has established a
novel strategy of evoking tumor immunity that would boost
other cancer immunotherapy strategies.
Alterations in Signal Transduction Molecules
Patients in advanced stages of cancer and mice with
large transplantable tumors have a compromised systemic
immune response with highly decreased delayed-type
hypersensitivity (DTH) responses. In this regard, NK and
T cells often exhibit alterations in their proliferative and
cytotoxic capacities as well as in cytokine secretion(97). Recent
observations showing alterations in signal transduction
molecules in T and NK cells from tumor-bearing mice and
cancer patients provide a molecular basis to better understand
this immune dysfunction. The original observation in mice
bearing a mouse colon carcinoma(98) showed an altered
pattern of protein tyrosinase phosphorylation, a reduction
of the protein tyrosine kinases p56lck and p59fyn, and a
decreased CD3-ζ chain. These findings have subsequently
been confirmed and extended to a variety of human tumors,
including renal, colorectal, ovarian, liver, gastric, pancreatic,
and cervical carcinomas and melanomas(99). 
Of particular interest is the correlation observed between
CD3-ζ expression and the disease stage in cancer patients(100).
The TCR-associated CD3-ζ chain is responsible for
transduction of signals delivered through the CD3-TCR
complex and, therefore, its expression is important for
activation of T cells(101). By quantitative flow cytometry
analysis, decreased or absent expression of the CD3-ζ chain
in CD4+ or CD8+ T cells as well as in NK cells was
demonstrated in patients with malignancies. A similar
finding was observed in tumor-infiltrating lymphocytes
(TILs). These observations have suggested that the tumor
microenvironment has negative effects on immune cells,
and that the failure of the host to eliminate tumors might
be a consequence of the impaired function of T cells,
including the inability of these cells to signal normally
upon TCR engagement(102). Interestingly, evidence has been
provided for tumor-induced degradation of the CD3-ζ
chain. It has been demonstrated that tumor cells can induce
activation of intracellular peptidases in T lymphocytes,
and that this tumor-induced enzymatic degradation is
responsible for decreased or absent expression of signal
transducing molecules, including the CD3-ζ chain in
activated T cells (103). On the other hand, a computer-assisted
analysis of the amino acid sequence of the CD3-ζ chain
has revealed the presence of sites sensitive to cleavage
by caspases, and it has been demonstrated that the CD3-
ζ chain is a substrate for proteolysis mediated by intracellular
caspases(104). These results indicate that tumor-induced
activation of caspases seems to be responsible for low or
absent expression of CD3-ζ and perhaps other signaling
molecules in T cells. Finally, other mechanisms, including
free oxygen radical generation within the tumor
microenvironment, have been proposed to account for
decreased CD3-ζ expression in cancer(105).
Although the mechanisms involved in tumor-induced
down-regulation of CD3-ζ expression in T cells are under
intense scrutiny, there are evidences indicating that direct
contact with tumor or tumor-derived factors might participate
in degradation of CD3-ζ and perhaps other signaling molecules.
In order to prevent signaling defects of T cells in tumor-
bearing hosts, it will be necessary to unravel the mechanism(s)
involved in tumor-T cell interactions. These studies are of
critical importance for the design of future immunotherapy
strategies.
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Novel Mechanisms of Tumor-immune Escape
Indoleamine 2,3 Deoxygenase (IDO)
An additional mechanism that mediates tumor-induced
immunosuppression includes the overexpression of the
IFN-γ-inducible enzyme, indoleamine 2,3-dioxygenase (IDO).
This enzyme is responsible for the catabolism of tryptophan
(the amino acid that is critical for T cell function) and a
competitive inhibitor of IDO, 1-methyl-tryptophan (1-MT),
can prevent tumor-immune escape(106). Uyttenhove and
colleagues demonstrated that expression of IDO by
immunogenic mouse tumor cells prevents their rejection
by preimmunized mice(106). This effect was accompanied by
a lack of accumulation of specific T cells at the tumor site
and could be partly reverted by systemic administration of
1-methyl-tryptophan, an inhibitor of IDO. These results
suggested that the efficacy of immunotherapy strategies
might be improved by concomitant administration of an
IDO inhibitor.
The STAT3 Pathway
Signal transducer and activator of transcription (STAT)-
family proteins are latent cytoplasmic transcription factors
that convey signals from cytokine and growth factor receptors
to the nucleus. It has been demonstrated that STAT3 signaling
in tumor cells suppresses both innate and adaptive anti-
tumor immune responses, further enhancing tumor
progression(107, 108). In addition a critical role has been
demonstrated for STAT3 in the generation of immune cell
tolerance(109). Proof-of-concept studies in cell culture and
animal models have validated STAT3 protein as a promising
molecular target for novel cancer therapies, including small-
molecule inhibitors of STAT3 signaling.
The PD-1/PD-L1 System and other negative
costimulatory signals
PD-1 is an inducible receptor expressed on CD4+ and
CD8+ T cells following activation. The expression of one
ligand for PD-1, designated PD-L1 or B7-H1, on tumor cells
of a variety of histological origins has suggested a potential
mechanism for tumor-immune escape(110). It has been
demonstrated that cancer cell-associated PD-L1 increases
apoptosis of antigen-specific human T cell clones in vitro
and in vivo(111). Thus, blockade of PD-L1 (B7-H1) might also
be a complementary therapy to augment tumor-specific T
cell responses(112). 
In addition, Kryczek and colleagues recently demonstrated
that B7-H4, a recently identified B7 family molecule, identifies
a novel suppressive macrophage population in human
ovarian carcinoma and that depletion of B7-H4+ tumor
macrophages may represent a novel strategy to enhance T-
cell mediated immunity in cancer(113). 
Galectin-1: The «Sweet Escape»
Galectins are animal lectins defined by shared consensus
amino acid sequences and affinity for β-galactose-containing
oligosaccharides(114). Recent evidence indicates that galectin-
1, a proto-type member of this family, has the potential to
inhibit T cell effector functions by regulating T cell apoptosis
and the Th1/ Th2 cytokine balance(115).
Expression of galectin-1, a prototype member of the
galectin family, has been well documented in many different
tumor types including astrocytoma, melanoma and prostate,
thyroid, colon, bladder and ovary carcinomas(116). Interestingly,
in most cases such expression correlates with the aggressiveness
of these tumors and the acquisition of metastatic phenotype. 
The immunoregulatory effects of galectin-1 and the
correlation between galectin-1 expression in cancer cells and
the aggressiveness of these tumors, prompted us to investigate
the role of galectin-1 in tumor-immune escape. We hypothesized
that tumor cells may impair T cell effector functions through
secretion of galectin-1 and that this mechanism may contribute
in tilting the balance toward an immunosuppressive
environment at the tumor site. By a combination of in vitro
and in vivo experiments using knockdown transfectants, we
established a link between galectin-1-mediated
immunoregulation and its contribution to tumor-immune
escape(117). Blockade of the inhibitory effects of galectin-1
within tumor tissue resulted in reduced tumor mass (an effect
which required intact CD4+ and CD8+ T cell responses) and
stimulated the generation of a tumor-specific T-cell response
in vivo. Our observations support the idea that galectin-1
may contribute to immune privilege of tumors by modulating
survival or polarization of effector T cells and suggest a
potential molecular target for manipulation of T-cell apoptosis
with potential implications in immunotherapy. Recently, Le
and collagues confirmed our findings demonstrating a link
between tumor hypoxia and galectin-1 expression in head
and neck squamous carcinoma cells(118). Interestingly, the
authors found a negative correlation between galectin-1
expression and presence of CD3+ T cells in tissue sections(118).
Challenges for the future will be to employ potent and
selective small inhibitors of galectin-1 and, in fact, molecules
with such properties have already been developed for galectin-
1 or other galectins(119-121). Furthermore, galectin-1 expression
can be modulated by chemotherapeutic and anti-metastatic
agents including low doses of Cy(122). A current challenge
is the design of more specific and potent galectin-1 inhibitors
for therapeutic purposes with no or minimal adverse effects.
Although galectin-1 still remains elusive in terms of our
understanding of its multifunctional modes of action, we
are moving closer to unraveling this mystery at a molecular
level and to design new therapeutic approaches directed
toward modulating its activities. Other galectins, including
galectin-2, galectin-3 and galectin-9 promote immune cell
apoptosis and modulate cytokine production in vitro, suggesting
their potential role in tumor-immune escape(114).
Other Mechanisms of Tumor-immune Escape
Other tumor-derived suppressive factors that are able
to impair T-cell function systemically include prostaglandin
E2 (PGE2), prostate-specific antigen (PSA), sialomucins
(MUC1) and RCAS1, a receptor-binding cancer antigen that
induces cell cycle arrest and apoptosis of target cells(123). 
IMMUNE STIMULATION
This phenomenon was first described by Prehn and
Lappé(124) who found that intermediate levels of antitumor
immune reactivity might often stimulate rather than inhibit
the development of certain tumor types(125,126). Shortly after,
Stewart and colleagues published several data on human
breast cancer(127,128) which agreed with Prehn’s postulation.
They found that certain types of human mammary
adenocarcinomas, but not other cancer types, are favored
in its growth properties by a mild immune response, at least
at the first stages of tumor evolution.
Several molecules secreted by, or expressed on the surface
of effector immune cells may be involved in the phenomenon
of immunostimulation. Similar to the cross-talk between
different immune cell types, cytokines produced by T cells
and the stroma can act as paracrine growth factors stimulating
tumor growth and progression. Different experimental
evidences support this reasoning. IL-10 and its receptor (IL-
10R) can stimulate the growth of metastatic cells of a B-cell
lymphoma, establishing an autocrine loop(129). Also, increased
production of IL-10, induced by CEA, enhances liver metastasis
in human colorectal carcinomas(130). Moreover, IL-4 stimulates
survival of thyroid cancer(131), head and neck squamous cell
carcinoma cell lines(132) and B-CLL cells(133). In addition, other
soluble factors released by immune cells and involved in
angiogenesis, including vascular endothelial growth factor
(VEGF)(134), may also play an important role in
immunostimulation. Interestingly, a positive association has
been observed between serum levels of VEGF and/or other
angiogenic molecules and cancer progression(135). In contrast,
other studies report a critical role for VEGF in the suppression
of dendritic cell differentiation and maturation(136). 
Taking into account the aforementioned experimental
evidence, the implementation of cancer immunotherapy
strategies should be preceded by a careful examination of
the tumor immunogenicity and the phenomena of tumor
escape and immunostimulation. In this regard, recent evidence
indicates that inflammatory cells can sculpt the immunogenicity
of different tumor types. This phenomenon led to the
identification by Schreiber and colleagues of the «Cancer
Immunoediting hypothesis»(137). This hypothesis proposes three
different mechanisms («The Three Es of immunoediting:
elimination, equilibrium and escape»), responsible of eliminating
tumors and sculpting the immunogenic phenotypes of
tumors that eventually form in immunocompetent hosts(137).
CONCLUDING REMARKS AND PERSPECTIVES
Research over the past few years has contributed to
increase enormously the available information about the
interactions between tumor cells and the immune system.
Currently we accept that tumors have smartly developed
a number of evasion strategies which, individually or in
combination, may enable these cells to thwart immune attack.
The identification of the mechanisms employed by each
tumor type will hopefully give the hints required to design
novel therapeutic strategies aimed at destroying the tumor
«fortress». Such therapeutic approaches should be aimed
at overcoming several potential mechanisms that individual
tumors may develop at different stages to overthrow or
avoid innate and adaptive immunity.
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